Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis

S. Bonvalot, A. Cavalcanti, C. Le Péchoux, P. Terrier, D. Vanel, J. Y. Blay, A. Le Cesne, D. Elias

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Purpose: In order to decrease loco-regional relapse after complete resection of peritoneal sarcomatosis (PS), the role of intraperitoneal chemotherapy (IPEC) was prospectively evaluated. Methods: Patients (pts) with completely resected PS were randomized between adjunction of IPEC or not. IPEC consisted of doxorubicin, 0.1 mg/kg and cisplatin, 15 mg/m2 per day for 5 consecutive days. Primary endpoint was survival, measured as time from randomization to death. The scheduled number of patients needed was 40 in order to detect a minimal increase of 40% overall survival with the adjunction of IPEC with a power of 80%. Results: Thirty-eight consecutive pts have been randomized, 19 in each group. Ratio of retroperitoneal (RPS) and visceral (VS) sarcomatosis were 9/10 and 6/13 in IPEC- and IPEC+ group, respectively. Histoprognostic grade, Sugarbaker's score and mean number of resected organs were similar in both groups. There were no toxic deaths and morbidity was similar in both groups (four pts in each group). The median follow-up is 60 months. The median local relapse-free, metastatic relapse-free survival and overall survival were identical in both groups (12.5, 18 and 29 months, respectively), with no difference between RPS and VS sarcomatosis. Conclusion: Administration of IPEC after a macroscopically complete surgery did not allow to increase greatly the outcome of pts. Complete surgery remains the cornerstone of the treatment of patients with sarcomatosis with best results for low grade sarcomatosis.

Original languageEnglish
Pages (from-to)917-923
Number of pages7
JournalEuropean Journal of Surgical Oncology
Volume31
Issue number8
DOIs
Publication statusPublished - Oct 2005

Fingerprint

Drug Therapy
Survival
Recurrence
Poisons
Random Allocation
Doxorubicin
Cisplatin
Morbidity
Therapeutics

Keywords

  • Intra peritoneal chemotherapy
  • Sarcoma
  • Sarcomatosis
  • Visceral sarcoma

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. / Bonvalot, S.; Cavalcanti, A.; Le Péchoux, C.; Terrier, P.; Vanel, D.; Blay, J. Y.; Le Cesne, A.; Elias, D.

In: European Journal of Surgical Oncology, Vol. 31, No. 8, 10.2005, p. 917-923.

Research output: Contribution to journalArticle

Bonvalot, S. ; Cavalcanti, A. ; Le Péchoux, C. ; Terrier, P. ; Vanel, D. ; Blay, J. Y. ; Le Cesne, A. ; Elias, D. / Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. In: European Journal of Surgical Oncology. 2005 ; Vol. 31, No. 8. pp. 917-923.
@article{ec7ceaf34ddb4a7b98148f955a7af7f8,
title = "Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis",
abstract = "Purpose: In order to decrease loco-regional relapse after complete resection of peritoneal sarcomatosis (PS), the role of intraperitoneal chemotherapy (IPEC) was prospectively evaluated. Methods: Patients (pts) with completely resected PS were randomized between adjunction of IPEC or not. IPEC consisted of doxorubicin, 0.1 mg/kg and cisplatin, 15 mg/m2 per day for 5 consecutive days. Primary endpoint was survival, measured as time from randomization to death. The scheduled number of patients needed was 40 in order to detect a minimal increase of 40{\%} overall survival with the adjunction of IPEC with a power of 80{\%}. Results: Thirty-eight consecutive pts have been randomized, 19 in each group. Ratio of retroperitoneal (RPS) and visceral (VS) sarcomatosis were 9/10 and 6/13 in IPEC- and IPEC+ group, respectively. Histoprognostic grade, Sugarbaker's score and mean number of resected organs were similar in both groups. There were no toxic deaths and morbidity was similar in both groups (four pts in each group). The median follow-up is 60 months. The median local relapse-free, metastatic relapse-free survival and overall survival were identical in both groups (12.5, 18 and 29 months, respectively), with no difference between RPS and VS sarcomatosis. Conclusion: Administration of IPEC after a macroscopically complete surgery did not allow to increase greatly the outcome of pts. Complete surgery remains the cornerstone of the treatment of patients with sarcomatosis with best results for low grade sarcomatosis.",
keywords = "Intra peritoneal chemotherapy, Sarcoma, Sarcomatosis, Visceral sarcoma",
author = "S. Bonvalot and A. Cavalcanti and {Le P{\'e}choux}, C. and P. Terrier and D. Vanel and Blay, {J. Y.} and {Le Cesne}, A. and D. Elias",
year = "2005",
month = "10",
doi = "10.1016/j.ejso.2005.04.010",
language = "English",
volume = "31",
pages = "917--923",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis

AU - Bonvalot, S.

AU - Cavalcanti, A.

AU - Le Péchoux, C.

AU - Terrier, P.

AU - Vanel, D.

AU - Blay, J. Y.

AU - Le Cesne, A.

AU - Elias, D.

PY - 2005/10

Y1 - 2005/10

N2 - Purpose: In order to decrease loco-regional relapse after complete resection of peritoneal sarcomatosis (PS), the role of intraperitoneal chemotherapy (IPEC) was prospectively evaluated. Methods: Patients (pts) with completely resected PS were randomized between adjunction of IPEC or not. IPEC consisted of doxorubicin, 0.1 mg/kg and cisplatin, 15 mg/m2 per day for 5 consecutive days. Primary endpoint was survival, measured as time from randomization to death. The scheduled number of patients needed was 40 in order to detect a minimal increase of 40% overall survival with the adjunction of IPEC with a power of 80%. Results: Thirty-eight consecutive pts have been randomized, 19 in each group. Ratio of retroperitoneal (RPS) and visceral (VS) sarcomatosis were 9/10 and 6/13 in IPEC- and IPEC+ group, respectively. Histoprognostic grade, Sugarbaker's score and mean number of resected organs were similar in both groups. There were no toxic deaths and morbidity was similar in both groups (four pts in each group). The median follow-up is 60 months. The median local relapse-free, metastatic relapse-free survival and overall survival were identical in both groups (12.5, 18 and 29 months, respectively), with no difference between RPS and VS sarcomatosis. Conclusion: Administration of IPEC after a macroscopically complete surgery did not allow to increase greatly the outcome of pts. Complete surgery remains the cornerstone of the treatment of patients with sarcomatosis with best results for low grade sarcomatosis.

AB - Purpose: In order to decrease loco-regional relapse after complete resection of peritoneal sarcomatosis (PS), the role of intraperitoneal chemotherapy (IPEC) was prospectively evaluated. Methods: Patients (pts) with completely resected PS were randomized between adjunction of IPEC or not. IPEC consisted of doxorubicin, 0.1 mg/kg and cisplatin, 15 mg/m2 per day for 5 consecutive days. Primary endpoint was survival, measured as time from randomization to death. The scheduled number of patients needed was 40 in order to detect a minimal increase of 40% overall survival with the adjunction of IPEC with a power of 80%. Results: Thirty-eight consecutive pts have been randomized, 19 in each group. Ratio of retroperitoneal (RPS) and visceral (VS) sarcomatosis were 9/10 and 6/13 in IPEC- and IPEC+ group, respectively. Histoprognostic grade, Sugarbaker's score and mean number of resected organs were similar in both groups. There were no toxic deaths and morbidity was similar in both groups (four pts in each group). The median follow-up is 60 months. The median local relapse-free, metastatic relapse-free survival and overall survival were identical in both groups (12.5, 18 and 29 months, respectively), with no difference between RPS and VS sarcomatosis. Conclusion: Administration of IPEC after a macroscopically complete surgery did not allow to increase greatly the outcome of pts. Complete surgery remains the cornerstone of the treatment of patients with sarcomatosis with best results for low grade sarcomatosis.

KW - Intra peritoneal chemotherapy

KW - Sarcoma

KW - Sarcomatosis

KW - Visceral sarcoma

UR - http://www.scopus.com/inward/record.url?scp=26444537915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444537915&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2005.04.010

DO - 10.1016/j.ejso.2005.04.010

M3 - Article

VL - 31

SP - 917

EP - 923

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 8

ER -